Neutrophil to Lymphocyte Ratio Predicts Overall Survival in Newly Diagnosed Hodgkin Lymphoma Patients-Single Centre Experience

Jelena Hajder¹, Natasa Stanisavljević¹, Dragomir Marisavljević¹,², Olivera Marković¹,², Radmila Zivković¹ and Vladimir Jurišić³
¹Medical Center “Bezanijska kosa”, Clinic for hematology and oncology, Serbia
²Faculty of Medical Sciences, University of Belgrade, Serbia
³Faculty of Medical Sciences, University of Kragujevac, Serbia

Abstract

Introduction: Neutrophil to lymphocyte ratio (NLR) has been identified as an independent prognostic factor for overall survival (OS) in various types of cancer.

Aim: The aim of this study was to establish prognostic significance of NLR in patients with newly diagnosed HL.

Methods: This retrospective analysis included 83 newly diagnosed patients with HL followed up from 2001-2015. ROC curve analysis was used to determine the optimal cut-off values for overall survival. Univariate and multivariate analysis was performed using the Cox proportional hazards regression to identify significant independent prognostic factors.

Results: The median follow-up after diagnosis was 92 months for the entire cohort (range 9-180 months) and 25.5 months for censored patients (range 1-81 months). Complete remission (CR) was achieved in 63 (79.7%) patients. An ROC curve of the NLR considering overall survival was generated showing AUC 0.655 ± 0.064 (95% CI, 0.536-0.724) with cut-off value of 4.3 (66% sensitivity and 59% specificity). Median OS for patients with NLR ≤ 4.3 was 61 months vs 50 months for patients with NLR ≥ 4.3, (p < 0.018). Multivariate analysis showed that independent prognostic variables for OS were high IPS (≥ 4) (p = 0.013), NLR ratio ≥ 4.3 (p = 0.007) and age ≥ 45, (p = 0.001). Patients in (un)favorable stage with NLR ≥ 4.3 in comparison to patients with NLR ≤ 4.3 had poorer survival in early unfavorable and advanced stage in contrast to advanced disease according to GHSG and EORTC staging system.

Conclusion: High NLR (≥ 4.3) is independent adverse prognostic factor for overall survival and should be considered as useful biomarker for precise prediction of clinical outcomes in early stage HL.

Keywords
Hodgkin lymphoma, Neutrophil, Lymphocyte, Neutrophil/Lymphocyte ratio, Prognosis, Early stage disease

List of Abbreviation
ABVD: Doxorubicin, Bleomycin, Vinblastine, Dacarbasine f; ABVD/MOPP: Hybrid Mechlorthamine, Vincristine, Procarbazine, and Prednisone; ALC: Absolute Lymphocyte Count; ANC: Absolute Neutrophil Count; BEACOPP: Bleomycin, Etoposide, Cyclophosphamide, Vincristine, Procarbazine, Prednisolone; CBC: Complete Blood Count; CR: Complete Remission; DLBCL: Diffuse Large B Cell Lymphoma; EORTC: European Organization for the Research and Treatment in Cancer; GHSG: German Hodgkin Study Group; HBV: Hepatitis B Virus; HCV: Hepatitis C Virus; HIV: Human Immunodeficiency Viruses; HL: Hodgkin Lymphoma; IPS: International Prognostic Score; LDH: Lactate Dehydrogenase; MTB: Mycobacterium Tuberculosis; NLR: Neutrophil to Lymphocyte Ratio; NS/MC: Nodular Sclerosis/Mixed Cellularity; OS: Overall Survival; PFS: Progression Free Survival; ROC: Receiver Operating Curve; WBC: Leukocyte, White Blood Cells

Copyright: © 2021 Hajder J, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
clinical risk factors to predict the risk for disease progression, relapse and death of patients with HL. The International Prognostic Score (IPS) uses seven prognostic factors to predict clinical outcomes in newly diagnosed HL patients [2]. Adverse prognostic factors in classic HL are age >45 years, stage IV disease, hemoglobin < 10 g/L, lymphocyte count < 0.6 \times 10^9/L, male sex, albumin < 40 g/L, white blood count > 15 \times 10^9/L. However, the IPS does not offer risk stratification for HL patients with limited disease (i.e., stages I and IIA, without constitutional symptoms and no bulky disease (≥10 cm in diameter)).

Inflammation has been identified to be a critical component of tumor progression, highlighting the role of the microenvironment, which is largely orchestrated by inflammatory cells as an indispensable participant in the neoplastic process, fostering proliferation, survival and migration [3]. For different solid tumors, as well as lymphomas, inflammation parameters, including leukocytes, neutrophils, lymphocytes and C-reactive protein have been associated with higher mortality rates [4-6]. Neutrophil to lymphocyte ratio (NLR) may reflect and clarify the immune response in systemic inflammatory response. NLR has been identified as an independent prognostic factor for overall survival (OS) and progression free survival (PFS) in various types of cancer, including colorectal cancer [7], pancreatic cancer [8], renal cell carcinoma [9] and diffuse large B cell lymphoma (DLBCL) [6,11]. We studied whether NLR at diagnosis can predict treatment response and overall survival in patients with classic HL. We then correlated the results of this analysis with other well known risk stratification systems.

Materials and Methods

This retrospective study included 83 consecutive patients diagnosed with HL at Medical Center "Bezanijska kosa", Belgrade, Serbia from 2001-2015. All patients met the following criteria: Pathohistologically confirmed HL without previous treatment, no previous history of malignancy, negativity for HIV, HBV, HCV or TBC infection with availability of laboratory and follow up data. Clinical data were retrieved from medical records. Treatment options and response criteria were based on standard guidelines. The ANC and ALC were obtained from the routine complete blood count (CBC) with 4-part differential counts (lymphocytes, monocytes, eosinophils, and neutrophils) using ABX Pentra DX-DF 120-HORIBA and NLR was calculated for each patient at diagnosis. The study was conducted according to the ethical guidelines following the Declaration of Helsinki. The institutional review committee approved our study protocol thereby following local biomedical research regulations. Statistical analysis Categorical variables were compared by using χ² test (2-sided Pearson or linear-By-linear association). Continuous variables were compared with the Mann-Whitney test.

The determination of optimal cut-off value for the ANC and ALC ratio in predicting overall survival was performed using the Receiver Operating Curve (ROC) method with determination of sensitivity and specificity of all cut-off values. OS was defined as time between the first day of diagnosis and the date of death from any cause or the last follow-up. Spearman’s rank correlation coefficient was used to describe the correlation between quantitative variables. The Kaplan-Meier method was used to estimate overall survival (OS). The log-rank test was used to compare the survival distributions. A multivariate analysis (Cox regression method) was performed to examine the effect of presumed prognostic factors on the overall survival. All statistical analyses were performed using the IBM SPSS version 22.0 statistical software program (SPSS, Chicago, IL). The results were considered to be statistically significant when the p value was less than 0.05.

Results

Patient characteristics

Patient age ranged from 18 to 80 years (median, 42 years). There were 44 (53%) male and 39 (47%) female patients. Nodular sclerosis/mixed cellularity (NS/MC) was the most common histological subtype, noted in 39 (47%) patients. Nodular sclerosis (NS) was the second common subtype, noted in 27 (32.5%) patients, followed by seven (8.4%) cases of the mixed cellularity, six (7.3%) cases of lymphocyte rich and four (4.8%) cases of the lymphocyte depletion. According to Ann Arbor staging system of HL, 3 (3.6%) patients were staged as stage I, 42 (50.6%) were stage II, 20 (24.1%) were stage III, and 18 (21.7%) were stage IV. German Hodgkin study Group (GSHL) early-stage favorable HL was noted in 16 (19.3%), early-stage (un)favorable HL in 28 (33.7%) and advanced-stage HL in 39 (47%) patients. European Organization for the Research and Treatment in Cancer (EORTC) early-stage favorable HL was noted in 13 (15.7%) patients and early-stage (un)favorable HL in 30 (36.1%) patients, whilst most patients (40 or 48.2%) were in advanced-stage HL on presentation. Extra-nodal lymphoma was present in 12 (14.5%) patients. Bulky disease (the largest lymph node >10 cm) was noted in 26 (31.3%) patients. B symptoms were present in 43 (53.8%) patients. IPS ≥ 4 was noted in 18 (21.7%) patients. Increased serum levels of lactate dehydrogenase (LDH) were found in 25 (30.1%) patients. Hemoglobin lower than 105 g/L was found in 21 (25.3%) patients and leukocytosis (WBC > 15 × 10^9) in 11 (13.3%) patients.

Patients were treated with standard chemotherapy and/or radiotherapy according to current international guidelines considering stage of the disease and risk factors. A majority of patients 47 (51%) received chemotherapy only and 44 (47.8%) patients were treated with chemo radiotherapy. Treatment regimens included doxorubicin, bleomycin, vinblastine, and dacarbasine (ABVD) for 75 (81.5%) patients, mechlothamine, vincristine, procarbazine, and prednisone (MOPP) for 1 (1.1%), ABVD/MOPP hybrid 9 (9.98%), bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine, procarbazine, and prednisolone (BEACOPP) for 7 (7.6%) patients. The median follow-up after diagnosis was 92 months for the entire cohort (range 9-180 months) and 25.5 months for censored patients (range 1-81 months). Complete remission (CR) was achieved in 63 (79.7%) patients (Table 1).

Determining the cut-off value of the NLR

An ROC curve of the NLR (ANC/ALC ratio) according to...
Table 1: Patients characteristics by NLR.

|                         | NLR ≤ 4.3 | NLR > 4.3 | significance |
|-------------------------|-----------|-----------|--------------|
|                         | n         | %         | n            | %          |
| Gender                  |           |           |              |            |
| male                    | 23        | 59.0      | 21           | 47.7       | ns          |
| female                  | 16        | 41.0      | 23           | 52.3       |             |
| Age                     |           |           |              |            |
| < 45 years              | 20        | 51.3      | 26           | 59.1       | ns          |
| ≥ 45 years              | 19        | 48.7      | 18           | 40.9       |             |
| Hemoglobin level        |           |           |              |            |
| > 10.5 g/dl             | 29        | 74.4      | 33           | 75.0       | ns          |
| < 10.5 g/dl             | 10        | 25.6      | 11           | 25.0       |             |
| White blood cell count  |           |           |              |            |
| < 15,000/µl             | 36        | 92.3      | 36           | 81.8       | ns          |
| ≥ 15,000/µl             | 3         | 7.7       | 8            | 18.2       |             |
| Lymphocyte count        |           |           |              |            |
| < 600/µl or < 8%        | 3         | 7.7       | 11           | 25.0       | 0.036*      |
| ≥ 600/µl or ≥ 8%        | 36        | 92.3      | 33           | 75.0       |             |
| Elevated LDH            |           |           |              |            |
| no                      | 27        | 69.2      | 31           | 70.5       | ns          |
| yes                     | 12        | 30.8      | 13           | 29.5       |             |
| B symptoms              |           |           |              |            |
| no                      | 20        | 52.6      | 17           | 40.5       | ns          |
| yes                     | 18        | 47.4      | 25           | 59.5       |             |
| PH subtype              |           |           |              |            |
| MC                      | 4         | 10.3      | 3            | 6.8        |             |
| NS                      | 17        | 43.6      | 10           | 22.7       | ns          |
| LD                      | 3         | 7.7       | 1            | 2.3        |             |
| LP                      | 3         | 7.7       | 3            | 6.8        |             |
| NS/MC                   | 12        | 30.8      | 27           | 61.4       |             |
| Clinical stage          |           |           |              |            |
| I                       | 1         | 2.6       | 2            | 4.5        | ns          |
| II                      | 23        | 59.0      | 19           | 43.2       |             |
| III                     | 9         | 23.1      | 11           | 25.0       |             |
| IV                      | 6         | 15.4      | 12           | 27.3       |             |
| ECOG                    |           |           |              |            |
| 0                       | 23        | 60.5      | 19           | 45.2       | ns          |
| 1                       | 9         | 23.7      | 12           | 28.6       |             |
| 2                       | 3         | 7.9       | 5            | 11.9       |             |
| 3                       | 3         | 7.9       | 4            | 9.5        |             |
| 4                       | 0         | 0.0       | 2            | 4.8        |             |
| IPS                     |           |           |              |            |
| < 4                     | 32        | 82.1      | 33           | 75.0       | ns          |
| ≥ 4                     | 7         | 17.9      | 11           | 25.0       |             |
| Bulky disease           |           |           |              |            |
| no                      | 29        | 74.4      | 28           | 63.6       | ns          |
| yes                     | 10        | 25.6      | 16           | 36.4       |             |
| Extranodal disease      |           |           |              |            |
| no                      | 34        | 87.2      | 37           | 84.1       | ns          |
| yes                     | 5         | 12.8      | 7            | 15.9       |             |
| GHSG                    |           |           |              |            |
| early favorable         | 10        | 25.6      | 6            | 13.6       | ns          |
| early unfavorable       | 13        | 33.3      | 15           | 34.1       |             |
| advanced                | 16        | 41.0      | 23           | 52.3       |             |
| EORTC                   |           |           |              |            |
| early favorable         | 8         | 20.5      | 5            | 11.4       | ns          |
| early unfavorable       | 16        | 41.0      | 14           | 31.8       |             |
| advanced                | 15        | 38.5      | 25           | 56.8       |             |
| Response to treatment (N = 79) |           |           |              |            |
| CR                      | 30        | 85.7      | 33           | 75.0       | ns          |
| PR, SD, progression     | 5         | 14.3      | 11           | 25.0       |             |
| Treatment outcome | dead | 8 | 20.5 | 21 | 48.8 | 0.007** |
|-------------------|------|---|------|----|------|--------|
| alive             | 31   | 79.5 | 22   | 51.2 |       |        |
| lost in follow up | 0    | 0.0 | 1    | 2.3 |      |        |

N: Number; NS: No Significance; CR: Complete Remission; PR: Partial Remission, SD: Stable Disease

Figure 1: (a,b) ROC curve of the NLR (ANC/ALC ratio) according to overall survival.
overall survival was generated to determine the cut-off value. The area under the curve was recorded as 0.655 ± 0.064 (95% CI, 0.536-0.724) (Figure 1). The NLR value of 4.3 corresponded to the maximum combined sensitivity and specificity on the ROC curve (66% sensitivity and 59% specificity). Therefore, median OS for patients with NLR ≤ 4.3 was 61 months and for subgroup with high NLR (NLR ≥ 4.3) median OS was 50 months. The clinic pathological features of the patients with NLR ≤ 4.3 and those with an NLR ≥ 4.3, are summarized in Table 1. There were 39 (47%) with NLR ≤ 4.3 and 44 (53%) with NLR ≥ 4.3.

### Prognostic significance of the NLR (ANC/ALC ratio)

There was significant difference in OS between patients with NLR ≥ 4.3 vs. patients with NLR ≤ 4.3 (p < 0.018) (Figure 2). Univariate analysis revealed that OS significantly correlated with older age (> 45 years), lymphopenia (< 600/µl vs. ≥ 600/µl), NLR ratio (continuous variable), NLR ≥ 4.3, male sex, advanced clinical stage, poor risk according IPS, GHSG and EORTC staging, and lower than CR as treatment response (Table 2). Multivariate analysis showed that independent

---

**Figure 2:** Comparison of OS of HL patients with NLR ≥ 4.3 and patients with NLR ≤ 4.3.

**Table 2:** Univariate analysis for OS in patients with classic HL.

| Cox analysis               | B    | SE    | P value | HR   | 95.0% CI for Exp(B) | Lower | Upper |
|---------------------------|------|-------|---------|------|--------------------|-------|-------|
| Univariate Analysis for OS|       |       |         |      |                   |       |       |
| Sex                       | F vs. M | 0.296 | 0.379  | 0.435 | 1.344              | 0.640 | 2.826 |
| Age                       | < 45 vs. ≥ 45 | 1.607 | 0.438  | 0.000 | 4.985              | 2.115 | 11.753 |
| Hemoglobin (g/L)          | ≥105 vs. ≤ 105 | 0.296 | 0.405  | 0.465 | 1.345              | 0.608 | 2.975 |
| Elevated LDH, U/L         | No vs yes | 0.281 | 0.395  | 0.476 | 1.325              | 0.611 | 2.871 |
| Lymphocyte count (×10^9/l)| ≥ 0.6 vs. < 0.6 | -1.140 | 0.421  | 0.007 | 0.320              | 0.140 | 0.730 |
| NLR ratio                 | continuous | 0.089 | 0.032  | 0.005 | 1.093              | 1.027 | 1.163 |
| NLR                       | ≤ 4.3 vs. ≥ 4.3 | 0.946 | 0.419  | 0.024 | 2.575              | 1.134 | 5.849 |
showed that NLR can reliably identify patients who will have a shorter survival, alone or in respect to other well-known staging systems. Second, most of the studies on the significance of NLR in HL reported so far are multicentric [12-14]. Our study is a single centre study with limitations of retrospective nature of the study designed and relatively small number of patients, but nevertheless informative enough and conclusive. In addition, it seems that NLR improve estimation of prognosis in early (un) favorable stage of the disease according to GHSG and EORTC staging systems.

**Discussion**

This study has few important aspects. First we clearly showed that NLR can reliably identify patients who will have a shorter survival, alone or in respect to other well-known staging systems. Second, most of the studies on the significance of NLR in HL reported so far are multicentric [12-14]. Our study is a single centre study with limitations of retrospective nature of the study designed and relatively small number of patients, but nevertheless informative enough and conclusive. In addition, it seems that NLR improve estimation of prognosis in early (un) favorable stage of the disease according to GHSG and EORTC staging systems.

Although HL is considered a highly curable disease, 20% of patients cannot be cured with standard first-line chemotherapy and have a dismal outcome. Since current clinical parameters do not allow precise risk stratification...
Pathologically, HL is characterized by the presence of a small number of diagnostic Reed-Sternberg cells in a background of bystander reactive cells composed of lymphocytes, neutrophils, macrophages, eosinophils, and plasma cells. Lymphopenia is related to adverse survival outcomes [17], as well as tumor-infiltrating lymphocytes and tumor-infiltrating macrophages that constitute the tumor microenvironment [12,18,19]. Tumor-infiltrating lymphocytes and tumor-infiltrating macrophages are reported to be prognostic factors for survival in patients with HL [16]. The tumor microenvironment and, in particular,

there is a continuing need for identification of new prognostic factors that may be useful for risk stratification and predicting the response to treatment [15]. To address this issue and better stratify the risk, tests for various prognostic factors have been suggested, including gene expression profiling [16], immunohistochemically analysis of biomarkers, and positron emission tomography [17]. But, not all countries have resources to implement these advanced and sophisticated methods. Current gold standard for risk stratification in HL worldwide is the IPS, but this prognostic score is generated for advanced HL.

In addition, as for any mathematical cutoff value applied to biological phenomenon, one has to be cautious when dealing with “borderline cases”. For example, hypothetical patients with HL and WBC of 14.9 x 10^9/l and lymphocyte count of 0.61 x 10^9/l accounts for zero points in IPS system, regardless of his obviously very high NLR. In addition, NLR should be used for more precise estimation of prognosis in “borderline cases” of HL as well as in clinical stage with carry specific treatment dilemmas, like early (un)favorable stage disease. All these were the reasons why we analyzed NLR in different disease stage according to GHSG and EORTC staging system. Our results clearly showed that NLR ≥ 4.3 can distinguish poorer prognosis in early (un)favorable stage in comparison to advanced stage disease.

Figure 4: (a,b) Comparison of GHSG (un)favorable early vs. advanced GHCG stage disease in relation to NLR (≤ 4.3 vs. ≥ 4.3).

Figure 5: (a,b) Comparison of EORTC (un)favorable early vs. advanced EORTC stage disease in relation to NLR (≤ 4.3 vs. ≥ 4.3).
the inflammatory response play an important role in cancer development and progression and may be associated with systemic inflammation. NLR can be used as a marker of systemic inflammation since it has long been known that the baseline raised white blood cell count (≥ 15 × 10^9/L) and lower lymphocyte count has a prognostic role in classic Hodgkin lymphoma.

The accumulation of neutrophils is related to increased cytokine levels, especially IL-8 [12,20] and it has been suggested that a high number of neutrophils may actually promote tumor growth and metastasis and/or inhibit lymphocyte activity, thereby counteracting the antitumor immune response [13,21]. These observations suggest that an imbalance in the ratio of neutrophil to lymphocyte in the peripheral blood of patients with cancer may be related to tumor development. However, the number of studies related to the clinical significance of NLR, especially on the long-term results of hematological malignancies are quite a few [14], when compared to those carried out with solid tumors [22]. Our single center study clearly showed that high NLR is associated with shorter overall survival in patients with newly diagnosed HL. The quick, accessible, inexpensive, easily applicable parameter is strong indicator of shorter survival in patients with advanced disease. However, comprehensive prospective studies in larger cohorts of HL patients are needed to evaluate prognostic significance of NLR in early stage disease. The authors declare that they have no conflict of interest.

References

1. Engert A, Younes A (2012) Hodgkin lymphoma: A comprehensive overview. Gallamini A, Hutchings M Functional imaging in Hodgkin lymphoma 107-123.

2. Hasenclever D, Diehl V (1998) A prognostic score for advanced Hodgkin’s disease. N Engl J Med 339: 1506-1514.

3. Coussens LM, Werb Z (2002) Inflammation and cancer. Nature 420: 860-867.

4. Cao Y, Shi YX, Chen JO, et al. (2012) Serum C-reactive protein as an important prognostic variable in patients with diffuse large B cell lymphoma. Tumour Biol 33: 1039-1044.

5. Mohri Y, Tanaka K, Ohi M, et al. (2010) Prognostic significance of host- and tumor-related factors in patients with gastric cancer. World J Surg 34: 285-290.

6. Troppan K, Deutsch A, Gerger A, et al. (2014) The derived neutrophil to lymphocyte ratio is an independent prognostic factor in patients with diffuse large B-cell lymphoma. Br J Cancer 110: 369-374.

7. Walsh SR, Cook EJ, Goulder F, et al. (2005) Neutrophil lymphocyte ratio as a prognostic factor in colorectal cancer. J Surg Oncol 91: 181-84.

8. Zhang DS, Wang DS, Wang ZQ, et al. (2012) Comparison of the prognostic values of various inflammation based factors in patients with pancreatic cancer. Med Oncol 29: 3092-3100.

9. Szkandera J, Absenger G, Liegl Atzwanger B, et al. (2013) Elevated preoperative neutrophil/lymphocyte ratio is associated with poor prognosis in soft-tissue sarcoma patients. Br J Cancer 108: 1677-1683.

10. Pichler M, Hutterer GC, Stojakovic T, et al. (2013b) High plasma fibrinogen level represents an independent negative prognostic factor regarding cancer-specific, metastasis-free, as well as overall survival in a European cohort of non-metastatic renal cell carcinoma patients. Br J Cancer 109: 1123-1129.

11. Porrata LF, Ristow K, Habermann T, et al. (2010) Predicting survival for diffuse large B-cell lymphoma patients using baseline neutrophil/lymphocyte ratio. Am J Hematol 85: 896-899.

12. Burak UZ (2016) Usefulness of baseline neutrophil to lymphocyte ratio (NLR) in Hematological malignancies. Global Journal of Hematology and Blood Transfusion 3: 10-15.

13. Young Wha Koh, Hyo Jeong Kang, Chansik Park, et al. (2012) Prognostic significance of the ratio of absolute neutrophil count to absolute lymphocyte count in classic Hodgkin lymphoma. Am J Clin Pathol 138: 846-854.

14. Reddy JP, Hernandez M, Gunther JR, et al. (2018) Pre-treatment neutrophil/lymphocyte ratio and platelet/lymphocyte ratio are prognostic of progression in early stage classical Hodgkin lymphoma. Br J Haematol 180: 545-549.

15. Derenzini E, Younes A (2011) Predicting treatment outcome in classical Hodgkin lymphoma: Genomic advances. Genome Med 3: 26.

16. Stedil C, Lee T, Shah SP, et al. (2010) Tumor-associated macrophages and survival in classic Hodgkin’s lymphoma. N Engl J Med 362: 875-885.

17. Mocikova H, Pytilik R, Markova J, et al. (2011) Pre-transplant position tomography in patients with relapsed Hodgkin lymphoma. Leuk Lymphoma 52: 1668-1674.

18. Alvaro Naranjo T, Lejeune M, Salvadó Usach MT, et al. (2005) Tumor-infiltrating cells as a prognostic factor in Hodgkin’s lymphoma: A quantitative tissue microarray study in a large retrospective cohort of 267 patients. Leuk Lymphoma 46: 1581-1591.

19. Schreck S, Friebel D, Buettner M, et al. (2009) Prognostic impact of tumour-infiltrating Th 2 and regulatory T cells in classical Hodgkin lymphoma. Hematol Oncol 27: 31-39.

20. Skinnider BF, Mak TW (2002) The role of cytokines in classical Hodgkin lymphoma. Hematol Oncol 181-84.

21. Rotondo R, Bertolotto M, Barisone G, et al. (2011) Exocytosis of azurophil and arginase 1 containing granules by activated polymorphonuclear neutrophils is required to inhibit T lymphocyte proliferation. J Leukoc Biol 89: 721-727.

22. Marcheselli R, Bari1 A, Tadmor T, et al. (2016) Neutrophil-lymphocyte ratio at diagnosis is an independent prognostic factor in patients with nodular sclerosis Hodgkin lymphoma: Results of a large multicenter study involving 990 patients. Hematol Oncol 1-6.

DOI: 10.36959/831/384

Copyright: © 2021 Hajder J, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.